{"id":816783,"date":"2025-02-24T10:41:08","date_gmt":"2025-02-24T15:41:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/"},"modified":"2025-02-24T10:41:08","modified_gmt":"2025-02-24T15:41:08","slug":"agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/","title":{"rendered":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting<\/b><\/p>\n<p class=\"bwalignc\"><i>Combination of Botensilimab\/Balstilimab with MiNK Therapeutics\u2019 AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in Refractory Gastric Cancer<\/i><\/p>\n<p>LEXINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAgenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics\u2019 agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in patients with refractory (2L+) gastric cancer (NCT06251973).<\/p>\n<p>\n\u201cThese latest data demonstrate the remarkable potential of combining BOT\/BAL with a novel iNKT cell therapy to broaden and intensify immune responses against resistant gastric tumors,\u201d said Dr. Dhan Chand, Vice President of Research at Agenus. \u201cBy driving strong IFN\u03b3 production, deep T-cell infiltration, and memory T-cell activation\u2014even in PD-1\u2013refractory patients\u2014the addition of agenT-797 to BOT\/BAL could redefine what\u2019s possible in late-line gastric cancer. We\u2019re particularly encouraged by how these therapies work in concert with standard-of-care chemotherapy to transform immunologically &#8216;cold&#8217; tumors into &#8216;hot&#8217; immune inflamed tumors, potentially offering a new therapeutic paradigm for patients facing this challenging disease.\u201d<\/p>\n<p><b>Highlights<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Broad Immune Activation<\/b>: The addition of MiNK\u2019s allogeneic iNKT therapy, agenT-797, to BOT\/BAL drove robust immune activation, including elevated interferon-gamma (IFN\u03b3) levels, indicating potent systemic engagement and overcoming immunosuppressive pathways in PD-1\u2013refractory gastric tumors.\n<\/li>\n<li><b>Enhanced T cell Infiltration and Memory T-Cell Expansion<\/b>: A marked increase in tumor-infiltrating lymphocytes (TILs), together with heightened peripheral memory T-cell activation, underscores the potential for long-lasting anti-tumor immunity when combining BOT\/BAL with agenT-797 (allo-iNKTs).\n<\/li>\n<li><b>Optimized Sequencing with Chemotherapy<\/b>: Early administration of agenT-797 alongside BOT\/BAL, before standard chemotherapy significantly amplifies immune responses, potentially reducing tumor recurrence through optimal T-cell priming, activation and mobilization.\n<\/li>\n<\/ul>\n<p><b>Presentation Details:<\/b><\/p>\n<p>\nAbstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)<\/p>\n<p>\nPresenting Author: Dr. Samuel Cytryn, Memorial Sloan Kettering Cancer Center, New York, New York<\/p>\n<p>\nOral Session: Proffered Papers, Session 2; 1:39-1:45 p.m. PST<\/p>\n<p>\nPoster Session: Poster Session, A; 1:45-4:45 p.m. PST<\/p>\n<p>\nDate: Monday, February 24th<\/p>\n<p>\nThe presentation will be available on the publications page of the Agenus website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fagenusbio.com%2Fpublications%2F&amp;esheet=54212510&amp;newsitemid=20250224368708&amp;lan=en-US&amp;anchor=https%3A%2F%2Fagenusbio.com%2Fpublications%2F&amp;index=1&amp;md5=e1018d29023daeaf341fc54edd11ab99\">https:\/\/agenusbio.com\/publications\/<\/a> following the start of the conference session.<\/p>\n<p><b>About Agenus<\/b><\/p>\n<p>\nAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54212510&amp;newsitemid=20250224368708&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=2&amp;md5=f53a04c3a297d7c84d1225b246e5e857\">www.agenusbio.com<\/a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.<\/p>\n<p><b>About Botensilimab (BOT)<\/b><\/p>\n<p>\nBotensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to \u201ccold\u201d tumors which generally respond poorly to standard of care or are refractory to conventional PD-1\/CTLA-4 therapies and investigational therapies.<\/p>\n<p>\nApproximately 1,100 patients have been treated with botensilimab and\/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus\u2019 investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54212510&amp;newsitemid=20250224368708&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=3&amp;md5=737d6ac087a04c7f71b4bd9882643cb5\">www.clinicaltrials.gov<\/a> with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.<\/p>\n<p><b>About Balstilimab (BAL)<\/b><\/p>\n<p>\nBalstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.<\/p>\n<p><b>About AgenT-797<\/b><\/p>\n<p>\nAgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as \u201cmaster regulators,\u201d combining the cytotoxic capabilities of NK cells with T-cell\u2013like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors.<\/p>\n<p>\nManufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F38281989%2F&amp;esheet=54212510&amp;newsitemid=20250224368708&amp;lan=en-US&amp;anchor=Oncogene.+2024&amp;index=4&amp;md5=fd98c2cce00fd405f5457aabaea2e794\">Oncogene. 2024<\/a>) and to combat inflammation in critically ill patients with severe respiratory pathology (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Fncomms&amp;esheet=54212510&amp;newsitemid=20250224368708&amp;lan=en-US&amp;anchor=Nature+Communications&amp;index=5&amp;md5=5dc4a3e3b58cbdff4d34f88cb27a4ce0\"><i>Nature Communications<\/i><\/a>. 2024).<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;hopes,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;forecasts,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; \u201cestablish,\u201d \u201cpotential,\u201d \u201csuperiority,\u201d \u201cbest in class,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250224368708\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250224368708\/en\/<\/a><\/span><\/p>\n<p><b>Investors<br \/>\n<\/b><br \/>917-362-1370<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor@agenusbio.com\">investor@agenusbio.com<\/a><\/p>\n<p><b>Media<br \/>\n<\/b><br \/>510-323-5188<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:communications@agenusbio.com\">communications@agenusbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250224368708\/en\/381089\/3\/2_Agenus-Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting Combination of Botensilimab\/Balstilimab with MiNK Therapeutics\u2019 AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in Refractory Gastric Cancer LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics\u2019 agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in patients with refractory (2L+) gastric cancer (NCT06251973). \u201cThese latest data demonstrate the remarkable potential of combining BOT\/BAL with a novel &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816783","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting Combination of Botensilimab\/Balstilimab with MiNK Therapeutics\u2019 AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in Refractory Gastric Cancer LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics\u2019 agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in patients with refractory (2L+) gastric cancer (NCT06251973). \u201cThese latest data demonstrate the remarkable potential of combining BOT\/BAL with a novel &hellip; Continue reading &quot;Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T15:41:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus Presents New Botensilimab\\\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting\",\"datePublished\":\"2025-02-24T15:41:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/\"},\"wordCount\":1048,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/\",\"name\":\"Agenus Presents New Botensilimab\\\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-24T15:41:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus Presents New Botensilimab\\\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Market Newsdesk","og_description":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting Combination of Botensilimab\/Balstilimab with MiNK Therapeutics\u2019 AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in Refractory Gastric Cancer LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics\u2019 agenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in patients with refractory (2L+) gastric cancer (NCT06251973). \u201cThese latest data demonstrate the remarkable potential of combining BOT\/BAL with a novel &hellip; Continue reading \"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T15:41:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting","datePublished":"2025-02-24T15:41:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/"},"wordCount":1048,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/","name":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-24T15:41:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250224368708r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-new-botensilimab-balstilimab-data-in-gastric-cancer-at-aacr-io-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus Presents New Botensilimab\/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816783"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816783\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}